Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Market Cap & Net Worth: Medacta Group SA (MEDGF)
Medacta Group SA (PINK:MEDGF) has a market capitalization of $1.67 Billion ($1.67 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #10244 globally and #4785 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medacta Group SA's stock price $83.91 by its total outstanding shares 19919300 (19.92 Million).
Medacta Group SA Market Cap History: 2019 to 2025
Medacta Group SA's market capitalization history from 2019 to 2025. Data shows growth from $1.55 Billion to $1.67 Billion (16.40% CAGR).
Medacta Group SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medacta Group SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.83x
Medacta Group SA's market cap is 2.83 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
22.93x
Medacta Group SA's market cap is 22.93 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.55 Billion | $310.62 Million | $11.86 Million | 4.98x | 130.42x |
| 2020 | $1.85 Billion | $302.49 Million | $37.09 Million | 6.10x | 49.77x |
| 2021 | $2.81 Billion | $363.13 Million | $51.52 Million | 7.73x | 54.51x |
| 2022 | $1.66 Billion | $437.12 Million | $46.25 Million | 3.79x | 35.79x |
| 2023 | $1.66 Billion | $510.78 Million | $47.36 Million | 3.25x | 35.06x |
| 2024 | $1.67 Billion | $590.58 Million | $72.89 Million | 2.83x | 22.93x |
Competitor Companies of MEDGF by Market Capitalization
Companies near Medacta Group SA in the global market cap rankings as of March 18, 2026.
Key companies related to Medacta Group SA by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Medacta Group SA Historical Marketcap From 2019 to 2025
Between 2019 and today, Medacta Group SA's market cap moved from $1.55 Billion to $ 1.67 Billion, with a yearly change of 16.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.67 Billion | 0.00% |
| 2024 | $1.67 Billion | +0.66% |
| 2023 | $1.66 Billion | +0.32% |
| 2022 | $1.66 Billion | -41.07% |
| 2021 | $2.81 Billion | +52.13% |
| 2020 | $1.85 Billion | +19.37% |
| 2019 | $1.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Medacta Group SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.67 Billion USD |
| MoneyControl | $1.67 Billion USD |
| MarketWatch | $1.67 Billion USD |
| marketcap.company | $1.67 Billion USD |
| Reuters | $1.67 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.